Propranolol and cancer

Abstract

Propranolol is a beta adrenergic receptor inhibitor showing clinical effects from treatment of hypertension to benign infantile hemangioma and used today for more aggressive vascular sarcomas and other cancers. Propranolol, a non-specific beta adrenergic blocking drug, inhibits the binding of catecholamines to receptors and proliferation of cancer cells. Thus, it is an important candidate for recycling in oncology. The anti-tumor activity of propranolol can be used for treatment and prophylaxis in different types of cancer. In this review, we discussed the prophylactic effects of propranolol on hemangioma, breast, pancreas, and prostate cancers.